TGN-020

• Description :

  TGN-020 is a selective Aquaporin 4 (AQP4) inhibitor with an IC50 of 3.1 μM[1][2]. TGN-020 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[3].TGN-020 alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats[4].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  PROTAC Linkers

• Type :

  Reference compound

• Related Pathways :

  PROTAC

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/tgn-020.html

• Purity :

  99.97

• Solubility :

  DMSO : 16.67 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC=CN=C1)NC2=NN=CS2

• Molecular Formula :

  C8H6N4OS

• Molecular Weight :

  206.23

• Precautions :

  H302

• References & Citations :

  [1]An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562|[2]Vincent J Huber, et al. Identification of aquaporin 4 inhibitors using in vitro and in silico methods. Bioorg Med Chem. 2009 Jan 1;17 (1) :411-7.|[3]Shou Oosuka, et al. Effects of an Aquaporin 4 Inhibitor, TGN-020, on Murine Diabetic Retina. Int J Mol Sci. 2020 Mar 27;21 (7) :2324.|[4]Jian Li, et al. TGN-020 alleviates edema and inhibits astrocyte activation and glial scar formation after spinal cord compression injury in rats. Life Sci. 2019 Apr 1;222:148-157.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  Store at room temperature 3 years

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Alkyl-Chain Linkers

• CAS Number :

  [51987-99-6]